NUAK2 Antibody

Code CSB-PA880931ESR2HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA880931ESR2HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA880931ESR2HU at dilution of 1:100

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NUAK2 Polyclonal antibody
Uniprot No.
Target Names
NUAK2
Alternative Names
DKFZp434J037 antibody; DKFZp686F01113 antibody; FLJ90349 antibody; NUAK family SNF1 like kinase 2 antibody; NUAK family SNF1-like kinase 2 antibody; Nuak2 antibody; NUAK2_HUMAN antibody; Omphalocele kinase 2 antibody; SNARK antibody; SNF1/AMP activated protein kinase antibody; SNF1/AMP kinase related kinase antibody; SNF1/AMP kinase-related kinase antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human NUAK family SNF1-like kinase 2 protein (479-628AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Polyclonal
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Able to phosphorylate 'Ser-464' of LATS1.
Gene References into Functions
  1. Data (including data from studies in knockout and transgenic mice) suggest that NUAK2/SNARK is involved in both adipose inflammation and energy metabolism in adipocytes; additionally, genome-wide association studies suggest that 2 SNPs in NUAK2/SNARK (rs4682880, rs4682676) are associated with obesity in women. PMID: 29298809
  2. miR143 inhibited the proliferation, migration and invasion of the glioblastoma cells by degrading NUAK2 in glioblastoma. PMID: 27081712
  3. Sucrose non-fermenting AMPK related kinase/Pentraxin 3 combined role in immunometabolic signaling and DNA damage response is proposed to accelerate cardiovascular complications in systemic lupus erythematosus patients PMID: 25732129
  4. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. PMID: 25832654
  5. The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-beta signaling. PMID: 23831117
  6. Activation of AMP-activated protein kinase protects the integrity of the blood-brain barrier by suppressing the induction of NADPH oxidase-derived superoxide anions. PMID: 22796592
  7. Considers possible roles of NUAK2 in tumorigenesis in general and suggest that NUAK2 has pivotal roles in acral melanomagenesis. PMID: 21911917
  8. MLCP (myosin light chain phosphatase) activation is counteracted by a previously unrecognized association between MRIP (myosin phosphatase Rho-interacting protein) and the inducible kinase NUAK2 PMID: 21242312
  9. This study further supports the importance of NUAK2 in cancer development and tumor progression, while AMPK has antioncogenic properties. PMID: 21460252
  10. Data show that SNARK is activated by muscle contraction and is a unique mediator of contraction-stimulated glucose transport in skeletal muscle. PMID: 20713714
  11. SNARK is an NF-kappaB-regulated anti-apoptotic gene that contributes to the tumor-promoting activity of CD95 in apoptosis-resistant tumor cells PMID: 15345718
  12. These data suggests different phosphorylation and regulation of MYPT1 activity by NUAK2. PMID: 18023418
  13. EBV LMP1 upregulated the expression of SNARK; SNARK expression increased drug resistance in response to doxorubicin increased of cancer cell survival PMID: 18452098
  14. The nuclear localizing SNARK altered transcriptome profiles and a considerable part of these alterations were canceled by the mutation of NLS, suggesting the ability of SNARK to modulate gene expression dependent on its nuclear localization. PMID: 18992219
  15. Skeletal muscle SNARK expression is increased in human obesity, and in response to metabolic stressors, but not type 2 diabetes. Partial SNARK depletion failed to modify either glucose or lipid metabolism. PMID: 19652946
  16. This study describes the cloning and characterization of the rat SNARK homolog, mapping of the human SNARK gene to 1q32, and a potential functional role as mediator of the cellular response to metabolic stress. PMID: 11284715

Show More

Hide All

Protein Families
Protein kinase superfamily, CAMK Ser/Thr protein kinase family, SNF1 subfamily
Database Links

HGNC: 29558

OMIM: 608131

KEGG: hsa:81788

STRING: 9606.ENSP00000356125

UniGene: Hs.497512

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*